Loading...
01/11 13:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerning factors: a decline in overall revenue, increased operating expenses, and a wider adjusted EBITDA loss. Although there are positive aspects like strong consumables revenue and cost-saving measures, the weak guidance for 2025 and uncertainties surrounding large projects and FDA submissions weigh heavily. The Q&A section further highlights these uncertainties, with management's vague responses not alleviating concerns. Without a clear path to growth and profitability, the stock is likely to experience a negative reaction.
Revenue $30.3 million, a decline of 5% year-over-year due to pressure on capital equipment and a decrease in large multimillion-dollar projects from pharma customers.
Consumables Revenue $18.1 million, up 6% year-over-year, driven by strong performance from products launched in the past 12 months.
Instrument Revenue $2.6 million, up 3% year-over-year, with 17 instruments placed in the quarter compared to 16 in Q1 2024.
Accelerator Lab Revenue $5.6 million, a decrease of 36% year-over-year, driven by a decline in large multimillion-dollar projects from pharma customers.
GAAP Gross Profit $16.4 million, with a margin of 54.1%.
Non-GAAP Gross Profit $15.1 million, with a non-GAAP gross margin of 49.7%, a decrease of 150 basis points year-over-year due to a non-cash charge to inventory reserves.
GAAP Operating Expenses $42.8 million, up $9.1 million year-over-year.
Non-GAAP Operating Expenses $33.8 million, up $2.3 million year-over-year.
Adjusted EBITDA Loss of $11.3 million, compared to a loss of $8.1 million in the prior year, including investments in Simoa ONE and Alzheimer's diagnostics.
Cash Balance $269.5 million, down $22.2 million from last year, with $13.2 million applied towards one-time items.
Adjusted Cash Burn $9 million, compared to $19.4 million in the prior year, a reduction of over 50%.
Expected Revenue for 2025 $120 million to $130 million, representing a decline of 5% to 13% year-over-year.
GAAP Gross Margin for 2025 Expected to be in the range of 55% to 59%.
Non-GAAP Gross Margin for 2025 Expected to be in the range of 50% to 54%, a reduction of 300 basis points from prior guidance.
Standalone Cash Usage for 2025 Expected to be between $35 million to $45 million from operations.
Expected Cash Balance at end of 2025 Approximately $120 million.
Cost Savings from Operational Efficiencies Expected to increase from $40 million to $55 million in 2026.
New Product Launches: In Q1, Quanterix launched four new immunology assays, building on the 20 new assays introduced last year.
Simoa ONE Platform: The Simoa ONE instrument and reagent platform is on track for release by year-end, expected to deliver up to 10x the sensitivity of existing systems.
LucentAD Complete Test: Expected to introduce pricing for the LucentAD Complete test later this summer, currently progressing through four clinical trials.
Market Expansion through Akoya Merger: The equity value of the Akoya merger is reduced from $201 million to $66 million, increasing Quanterix's ownership from 70% to 84%.
Expansion into Adjacent Markets: Quanterix is expanding its addressable market from $1 billion to $5 billion through the Akoya acquisition.
Alzheimer's Diagnostics Collaboration: New collaboration with ARUP Laboratories to offer the pTau217 blood test for Alzheimer's disease.
Operational Efficiencies: Announced a $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026.
Cash Usage Improvement: Adjusted cash burn reduced to $9 million in Q1, over 50% improvement compared to last year.
Strategic Focus Areas: Focusing on neurology, oncology, and immunology for growth, with a commitment to achieving positive cash flow by 2026.
Democratizing Access to Technology: Starting in 2026, customers will access Simoa ONE assay kits on existing flow cytometers, broadening market reach.
Market Environment: The company has revised its guidance conservatively due to the broader macro funding environment, indicating potential risks related to economic factors affecting revenue.
Academic Funding: Approximately 22% of revenues are indexed to U.S. academic customers, with a projected 20% reduction in NIH funding levels, implying significant pressure on revenue.
Tariffs: The company anticipates a 100 basis point revenue pressure from tariffs, which could impact overall financial performance.
Pharma Spending: There is a noted conservatism among biopharma and biotech customers, leading to project pushouts and smaller ticket sizes, which could affect revenue from the Accelerator lab.
Accelerator Lab Revenue: A significant decline of 36% in Accelerator lab revenue was reported, driven by a decrease in large multimillion-dollar projects from pharma customers.
Gross Margin: The company expects a reduction in gross margin due to lower revenue, particularly in the high-margin Accelerator business, which could impact profitability.
Cash Flow: Despite a commitment to achieving positive cash flow by 2026, the company is currently experiencing cash burn, which poses a risk to financial stability.
Strategic Initiatives: 1. Launch of four new immunology assays in Q1, building on 20 new assays from last year, contributing to the highest consumables revenue quarter. 2. Introduction of Simoa ONE platform expected by year-end, offering up to 10x sensitivity improvement and expanded multiplexing capabilities. 3. Progress in Alzheimer's diagnostics with new collaborations, including a partnership with ARUP Laboratories for the pTau217 blood test.
Merger with Akoya Biosciences: Amended transaction reduces equity value from $201 million to $66 million, increasing Quanterix's ownership from 70% to 84%. Expected contribution from Akoya is 37% to top line and 40% to gross profit.
Revenue Guidance: 2025 revenue expected in the range of $120 million to $130 million, reflecting a decline of 5% to 13%.
Gross Margin Guidance: GAAP gross margin expected to be 55% to 59%, non-GAAP gross margin expected to be 50% to 54%.
Cash Flow Outlook: Positive cash flow expected by 2026 with a cash balance exceeding $100 million.
Cost Reduction Initiatives: Announced $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026.
Shareholder Return Plan: Quanterix announced a $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026. This is part of their commitment to achieving positive cash flow by 2026, supported by a balance sheet exceeding $100 million.
Equity Value Reduction: The equity value of the pending merger with Akoya Biosciences was reduced by 67% from $201 million to $66 million, increasing Quanterix's shareholder ownership of the combined company from 70% to 84%.
The earnings call summary shows mixed signals. The company has optimistic guidance and potential market expansion, but faces current financial challenges with losses and reduced cash position. The Q&A highlights concerns about government shutdown impact, market uncertainties, and lack of specific guidance. Despite these, there are positive notes on synergies, Medicare traction, and cross-selling opportunities. However, the lack of guidance and financial losses balance out the positives, leading to a neutral sentiment.
The earnings call reveals significant challenges, including a substantial revenue decline, goodwill impairment, and increased operational expenses. Despite some positive developments like a rise in sales to diagnostics partners, the overall financial performance is concerning, with a notable loss in adjusted EBITDA. The Q&A section suggests some optimism but also highlights ongoing market uncertainties and dependence on external conditions. The strategic initiatives and cost reductions may offer future benefits, but current financial metrics and guidance indicate a negative outlook for the stock price in the short term.
The earnings call reveals mixed financial performance, with declining revenue and increasing losses, despite some positive aspects like consumables growth and cost reduction plans. The Q&A highlights concerns about declining large projects and economic pressures, while management's vague responses add uncertainty. The 2025 guidance shows modest growth expectations, but the lack of strong financial performance and cautious market environment suggest a negative stock reaction.
The earnings call reveals several concerning factors: a decline in overall revenue, increased operating expenses, and a wider adjusted EBITDA loss. Although there are positive aspects like strong consumables revenue and cost-saving measures, the weak guidance for 2025 and uncertainties surrounding large projects and FDA submissions weigh heavily. The Q&A section further highlights these uncertainties, with management's vague responses not alleviating concerns. Without a clear path to growth and profitability, the stock is likely to experience a negative reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
